Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

NVIDIA To $225? Plus Raymond James Cuts PT On This Stock By 81%

Published 11/11/2022, 14:19
Updated 11/11/2022, 15:40
© Reuters.  NVIDIA To $225? Plus Raymond James Cuts PT On This Stock By 81%

Benzinga -

  • Oppenheimer cut the price target on NVIDIA Corporation (NASDAQ: NASDAQ:NVDA) from $250 to $225. Oppenheimer analyst Rick Schafer maintained an Outperform rating on the stock. NVIDIA shares rose 0.9% to $158.86 in pre-market trading.
  • Raymond James cut the price target for Jounce Therapeutics, Inc. (NASDAQ: JNCE) from $16 to $3. Raymond James analyst Steven Seedhouse downgraded the stock from Strong Buy to Outperform. Jounce Therapeutics shares fell 41.2% to close at $1.17 on Thursday.
  • Jefferies cut the price target on Outbrain Inc. (NASDAQ: OB) from $6.5 to $4. Outbrain shares jumped 17.3% to close at $4.40 on Thursday.
  • Raymond James slashed the price target for NeoGenomics, Inc. (NASDAQ: NEO) from $15 to $12. NeoGenomics shares rose 2.6% to $10.34 in pre-market trading.
  • Keybanc slashed the price target for STERIS plc (NYSE: STE) from $240 to $210. STERIS shares gained 5.2% to close at $169.27 on Thursday.
  • Piper Sandler boosted the price target on Wix.com Ltd. (NYSE: WIX) from $78 to $80. Wix.com shares gained 0.4% to $84.00 in pre-market trading.
  • SVB Leerink cut the price target on Landos Biopharma, Inc. (NASDAQ: LABP) from $3 to $2. Landos Biopharma shares jumped 17.4% to close at $0.27 on Thursday.
Check out this: $10 Million Bet On Rain Therapeutics? Check Out These 4 Stocks Insiders Are Buying

Don’t forget to check out our premarket coverage here .

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.